Soon Mining Ltd (SMG)

0.200 0.000 (0.00%)
Closed AUD Disclaimer

Soon Mining Ltd Company Profile

Equity Type
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Contact Information
Watertown,02472 United States
617 926 5000
617 926 5050
Top Executives
David Robert Guyer 63 2019 Independent Director
Sophie J. Bakri 0 2021 Member of Executive Scientific Advisory Board
Carl D. Regillo 0 2021 Chairman of Executive Scientific Advisory Board
Usha Chakravarthy 0 2024 Member of Scientific Advisory Board
Frank G. Holz 0 2024 Member of Scientific Advisory Board
Karen Zaderej 62 2022 Independent Director
Rishi P. Singh 0 2021 Member of Executive Scientific Advisory Board
Glenn J. Jaffe 0 2021 Member of Executive Scientific Advisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.